Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
Authors
Keywords
-
Journal
BMC CANCER
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-15
DOI
10.1186/s12885-020-07760-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism
- (2020) Takahiro Nomoto et al. Science Advances
- Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy
- (2020) Jacques Rouanet et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Annexin A1: A double-edged sword as novel cancer biomarker
- (2020) Zhuqiong Fu et al. CLINICA CHIMICA ACTA
- Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
- (2020) Kevin L. Allen et al. PLoS One
- Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours
- (2020) Motohiro Nonaka et al. BRITISH JOURNAL OF CANCER
- Annexin-A1 – A Blessing or a Curse in Cancer?
- (2019) Sok Lin Foo et al. TRENDS IN MOLECULAR MEDICINE
- Advancements of Annexin A1 in inflammation and tumorigenesis
- (2019) Gang Shao et al. OncoTargets and Therapy
- Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era
- (2019) Minoru Suzuki International Journal of Clinical Oncology
- Annexin A1 expression is correlated with malignant potential of renal cell carcinoma
- (2018) Mariko Yamanoi et al. INTERNATIONAL JOURNAL OF UROLOGY
- Annexin A1 localization and its relevance to cancer
- (2016) Z. Boudhraa et al. CLINICAL SCIENCE
- Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1
- (2016) Erika Vacchelli et al. OncoImmunology
- IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance
- (2015) De-Hong Yu et al. BIOCONJUGATE CHEMISTRY
- Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model
- (2015) Yoshiya Iguchi et al. BIOMATERIALS
- Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2
- (2015) Printip Wongthai et al. CANCER SCIENCE
- Preliminary evaluation of novel 18F-AlF-NOTA-IF7 as a tumor imaging agent
- (2015) Xiaobo Gu et al. JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
- Regulatory Mechanisms of Annexin-Induced Chemotherapy Resistance in Cisplatin Resistant Lung Adenocarcinoma
- (2014) Chao Wang et al. Asian Pacific Journal of Cancer Prevention
- Expression of the Annexin A1 gene is associated with suppression of growth, invasion and metastasis of nasopharyngeal carcinoma
- (2014) AIFENG LIU et al. Molecular Medicine Reports
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide
- (2011) S. Hatakeyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice
- (2009) M. Yi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started